We're aware of a cyber security incident affecting the electronic prescriptions provider MediSecure. The eRX Script Exchange (eRX) and the National Prescription Delivery Service (NPDS) continue to operate as usual and have not been impacted. Find out more and read our statement here.

Red Book

Communicable diseases


Age range chart

Birth 0-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 >65

Immunisation is recommended from birth for all children, and at particular ages throughout life, according to the Australian immunisation handbook (this is updated regularly).

Consent should be sought from someone with legal capacity before each vaccination. The individual providing consent should have the intellectual capacity to understand specific information and agree voluntarily without pressure, coercion or manipulation. The consent process should include written advice about benefits and harms of the vaccines, risk of not having the vaccine, and what to do after receiving the vaccine. 

Information on providing valid consent is available within the Australian Immunisation handbook.

The National Immunisation Program Schedule (NIPS) lists the recommended funded vaccines for all Australian residents. There may be other vaccines that are not funded but are recommended in the Australian immunisation handbook, depending on occupation or travel. There may be variability in vaccines recommended/funded (eg hepatitis A vaccine).

Adults or children who develop asplenia, human immunodeficiency virus (HIV) infection or a haematological malignancy, or who have received a bone marrow or other transplant, may not be fit for some vaccinations, or may require additional or repeat vaccinations.

What are the key equity issues and who is at risk?

GPs need to be aware of groups with lower levels of age-appropriate immunisation.3 Socioeconomic characteristics associated with lower immunisation rates at 12 months4 include:

  • being Aboriginal or Torres Strait Islander
  • being born overseas
  • no private health insurance
  • being in the highest or lowest socioeconomic quintile
  • being of low birth weight and singleton birth.

All of these factors were also associated with lower immunisation coverage at 24 months, with the exception of low birth weight, which was only significant in the very low birth weight category.

What can GPs do?

Evidence supports a number of strategies in improving immunisation rates that could reduce inequities if efforts were focused on at-risk groups:

  • audit of immunisation coverage of at-risk groups in the practice
  • use of recall-and-reminder systems and catch-up plans, with a focus on at-risk groups
  • integrating vaccination status checks into routine health assessments for those target population groups.

 Summary of the main requirements from the National Immunisation Program Schedule

Table 6.1.1

Summary of the main requirements from the National Immunisation Program Schedule

Vaccines recommended but not funded in National Immunisation Program

Table 6.1.2

Vaccines recommended but not funded in National Immunisation Program

Immunisation information resources include:

Notification of adverse events

The reporting of adverse events following vaccinations varies geographically. It is possible to report directly to the Therapeutic Goods Administration (TGA) from anywhere in Australia or by telephone on 1800 044 114

  1. Community Preventive Services Task Force (USA). Recommendation for use of immunization information systems to increase vaccination rates. J Public Health Manag Pract 2015;21(3):249–52.
  2. Department of Health. Update: Expansion of Australia’s immunisation registers. Canberra: DoH, 2015 [Accessed 13 May 2016].
  3. Ward K, Chow MYK, King C, Leask J. Strategies to improve vaccination uptake in Australia, a systematic review of types and effectiveness. Aust N Z J Public Health 2012;36(4):369–77.
  4. Haynes K, Stone C. Predictors of incomplete immunisation in Victorian children. Aust N Z J Public Health 2004;28(1):72–79.
  5. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. HIV, viral hepatitis and STIs: A guide for primary care. Sydney: ASHM, 2014.
  6. Kong FY, Guy RJ, Hocking JS, et al. Australian general practitioner chlamydia testing rates among young people. Med J Aust 2011;194(5):249–52.
  7. Pavlin NL, Parker R, Fairley CK, Gunn JM, Hocking J. Take the sex out of STI screening! Views of young women on implementing chlamydia screening in general practice. BMC Infect Dis 2008;8:62.
  8. Preswell N, Barton D. Taking a sexual history. Aust Fam Physician 2000;29(5):533–39.
  9. Department of Health. Third national sexually transmissible infections strategy 2014–2017. Canberra: DoH, 2014 nsf/Content/ohp-bbvs-sti [Accessed 23 May 2016].
  10. Guy RJ, Ali H, Liu B, Hocking J, Donovan B, Kaldor J. Genital chlamydia infection in young people: A review of the evidence. Sydney: The Kirby Institute, 2011.
  11. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2015. Sydney: The Kirby Institute, 2015.
  12. Goldenring J, Rosen D. Getting into adolescent heads: An essential update. Contemp Pediatrics 2004;21(64):64–90.
  13. Hocking J, Fairley C. Need for screening for genital chlamydia trachomatis infection in Australia. Aust N Z J Public Health 2003;27(1):80–81.
  14. Meyers D, Wolff T, Gregory K, Marion L. USPSTF recommendations for STI screening. Am Fam Physician 2008;77(6):819–24.
  15. Cook RL, Hutchison SL, Ostergaard L. Systematic review: Noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005;142(11):914–25.
  16. Templeton DJ, Read P, Varma R, Bourne C. Australian sexually transmissible infection and HIV testing guidelines for asymptomatic men who have sex with men 2014: A review of the evidence. Sex Health 2014;11(3):217–29.
  17. Australian Health Ministers’ Advisory Council. Clinical practice guidelines: Antenatal care – Module II. Canberra: AHMAC, 2014.
  18. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Routine antenatal assessment in the absence of pregnancy complications. East Melbourne, Vic: RANZCOG, 2016 html#obstetrics [Accessed 28 April 2016].
  19. Cheney K, Wray L. Chlamydia and associated factors in an under 20s antenatal population. Aust NZ J Obstet Gynaecol 2008;48(1):40–43.
  20. Chen MY, Fairley CK, De Guingand D, et al. Screening pregnant women for chlamydia: What are the predictors of infection? Sex Transm Infect 2009;85(1):31–35.
  21. Scholes D, Stergachis A, Heidrich FE, Andrilla H. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Eng J Med 1996;334(21):1362–66.
  22. Queensland Health. Indigenous sexual health service report for Brisbane Southside. Brisbane: Communicable Disease Unit, 2004.
  23. Low N, McCarthy A, Macleod J, Salisbury C. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess 2007;11(8):1–165.
  24. Heal C, Jones B, Veitch C, Lamb S, Hodgens S. Screening for chlamydia in general practice. Aust Fam Physician 2002;31(8):779–82.
  25. Hayman N. Chlamydia PCR screening in an Indigenous health general practice clinic in Brisbane 2002–3. Brisbane, 2004.
  26. Uddin RN, Ryder N, McNulty AM, Wray L, Donovan B. Trichomonas vaginalis infection among women in a low prevalence setting. Sex Health 2011;8(1):65–68.
  27. The Kirby Institute. Bloodborne viral and sexually transmitted infections in Aboriginal and Torres Strait Islander people: Surveillance and evaluation report. Sydney: The Kirby Institute, 2014.
  28. Whiley DM, Garland SM, Harnett G, et al. Exploring ‘best practice’ for nucleic acid detection of Neisseria gonorrhoeae. Sex Health 2008;5(1):17–23.
  29. Whittington WL, Kent C, Kissinger P, Oh MK. Determinants of persistent and recurrent chlamydia trachomatis infection in young women: Results of a multicenter cohort study. Sex Transm Dis 2001;28(2):117–23.
  30. Orr DP, Johnston K, Brizendine E, Katz B. Subsequent sexually transmitted infection in urban adolescents and young adults. Arch Pediatr Adolesc Med 2001;155(8):947–53.
  31. Guy R, Wand H, Franklin N, et al. Re-testing for chlamydia at sexual health services in Australia, 2004–08. Sex Health 2011;8(2):242–47.
  32. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. MMWR 2006;55:38–40.
  33. Kwan B, Ryder N, Knight V, et al. Sensitivity of 20-minute voiding intervals in men testing for Chlamydia trachomatis. Sex Transm Dis 2012;39(5):405–06.
  34. Watson E, Templeton A, Russell I, Paavonen J. The accuracy and efficacy of screening tests for Chlamydia trachomatis: A systematic review. J Med Microbiol 2002;51(12):1021–31.
  35. Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually transmitted infections, including HIV. Cochrane Database Syst Rev 2013;10:CD002843.
  36. Trelle S, Shang A, Nartey L, Cassel J, Low N. Improved effectiveness of partner notification for patients with sexually transmitted infections: Systematic review. BMJ 2007;334(7589):354.
  37. Burnet Insitute. Partner notification of sexually transmitted infections in New South Wales: An informed literature review. Melbourne: Centre for Population Health, 2010 NSW_STI_PN_PDF.pdf [Accessed 28 January 2016].
  38. Honey E, Augood C, Templeton A, et al. Cost effectiveness of screening for Chlamydia trachomatis: A review of published studies. Sex Transm Infect 2002;78(6):406–12.
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log